Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure
Leo Pharma said it will pay Japan’s Tanabe Pharma up to $435 million in upfront and near-term payments to license an oral drug for a pair of genetic light-sensitive skin diseases. The Danish biotech will ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Leo Pharma buys rare skin disease drug in $435M deal biopharmadive.com